PRATHERAPEUTISCHE CHEMOSENSIBILITATSTESTUNG DES OVARIALKARZINOMS UND MOGLICHKEITEN DER KLINISCHEN ANWENDUNG

Translated title of the contribution: Pretreatment sensitivity testing of chemotherapeutic agents for ovarian cancer and possibilities of clinical application

Z. Hernádi, G. Pasti, L. Lampe, B. Juhasz

Research output: Contribution to journalArticle

Abstract

The authors report on their experiences concerning in vitro clonogenic assay performed according to Hamburger and Salmon on solid tumor tissue samples (13 cases) and ascites cells (5 cases) obtained from 16 ovarian cancer patients. From the 13 solid tumors they obtained a single cell suspension with sufficient numbers of cells in each case. Colony formation was observed in 10 out of 18 specimens. Dose-response curves were determined after incubation of cells with different concentrations of the following drugs: cis-platin, adriamycin and melphalan. Patients were treated with CAP combination chemotherapy. The correlation between clinical responses and in vitro sensitivity was evaluated retrospectively. The analysis of the in vitro-in vivo correlation showed that in case of in vitro resistance against two components of the CAP combination the tumor progressed during CAP treatment. In case of in vitro resistance against one component, except cis-platin, CAP therapy could cause even complete remission. With in vitro cis-platin resistance the maximum response with CAP treatment was partial remission.

Original languageGerman
Pages (from-to)1065-1071
Number of pages7
JournalZentralblatt fur Gynakologie
Volume107
Issue number17
Publication statusPublished - 1985

Fingerprint

Ovarian Neoplasms
Neoplasms
Melphalan
Salmon
Combination Drug Therapy
Ascites
Doxorubicin
In Vitro Techniques
Suspensions
Therapeutics
Cell Count
Pharmaceutical Preparations
CAP protocol 2

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

PRATHERAPEUTISCHE CHEMOSENSIBILITATSTESTUNG DES OVARIALKARZINOMS UND MOGLICHKEITEN DER KLINISCHEN ANWENDUNG. / Hernádi, Z.; Pasti, G.; Lampe, L.; Juhasz, B.

In: Zentralblatt fur Gynakologie, Vol. 107, No. 17, 1985, p. 1065-1071.

Research output: Contribution to journalArticle

@article{8b6c872283d54cebb5267586062a195d,
title = "PRATHERAPEUTISCHE CHEMOSENSIBILITATSTESTUNG DES OVARIALKARZINOMS UND MOGLICHKEITEN DER KLINISCHEN ANWENDUNG",
abstract = "The authors report on their experiences concerning in vitro clonogenic assay performed according to Hamburger and Salmon on solid tumor tissue samples (13 cases) and ascites cells (5 cases) obtained from 16 ovarian cancer patients. From the 13 solid tumors they obtained a single cell suspension with sufficient numbers of cells in each case. Colony formation was observed in 10 out of 18 specimens. Dose-response curves were determined after incubation of cells with different concentrations of the following drugs: cis-platin, adriamycin and melphalan. Patients were treated with CAP combination chemotherapy. The correlation between clinical responses and in vitro sensitivity was evaluated retrospectively. The analysis of the in vitro-in vivo correlation showed that in case of in vitro resistance against two components of the CAP combination the tumor progressed during CAP treatment. In case of in vitro resistance against one component, except cis-platin, CAP therapy could cause even complete remission. With in vitro cis-platin resistance the maximum response with CAP treatment was partial remission.",
author = "Z. Hern{\'a}di and G. Pasti and L. Lampe and B. Juhasz",
year = "1985",
language = "German",
volume = "107",
pages = "1065--1071",
journal = "Aktuelle Dermatologie",
issn = "0340-2541",
publisher = "Georg Thieme Verlag",
number = "17",

}

TY - JOUR

T1 - PRATHERAPEUTISCHE CHEMOSENSIBILITATSTESTUNG DES OVARIALKARZINOMS UND MOGLICHKEITEN DER KLINISCHEN ANWENDUNG

AU - Hernádi, Z.

AU - Pasti, G.

AU - Lampe, L.

AU - Juhasz, B.

PY - 1985

Y1 - 1985

N2 - The authors report on their experiences concerning in vitro clonogenic assay performed according to Hamburger and Salmon on solid tumor tissue samples (13 cases) and ascites cells (5 cases) obtained from 16 ovarian cancer patients. From the 13 solid tumors they obtained a single cell suspension with sufficient numbers of cells in each case. Colony formation was observed in 10 out of 18 specimens. Dose-response curves were determined after incubation of cells with different concentrations of the following drugs: cis-platin, adriamycin and melphalan. Patients were treated with CAP combination chemotherapy. The correlation between clinical responses and in vitro sensitivity was evaluated retrospectively. The analysis of the in vitro-in vivo correlation showed that in case of in vitro resistance against two components of the CAP combination the tumor progressed during CAP treatment. In case of in vitro resistance against one component, except cis-platin, CAP therapy could cause even complete remission. With in vitro cis-platin resistance the maximum response with CAP treatment was partial remission.

AB - The authors report on their experiences concerning in vitro clonogenic assay performed according to Hamburger and Salmon on solid tumor tissue samples (13 cases) and ascites cells (5 cases) obtained from 16 ovarian cancer patients. From the 13 solid tumors they obtained a single cell suspension with sufficient numbers of cells in each case. Colony formation was observed in 10 out of 18 specimens. Dose-response curves were determined after incubation of cells with different concentrations of the following drugs: cis-platin, adriamycin and melphalan. Patients were treated with CAP combination chemotherapy. The correlation between clinical responses and in vitro sensitivity was evaluated retrospectively. The analysis of the in vitro-in vivo correlation showed that in case of in vitro resistance against two components of the CAP combination the tumor progressed during CAP treatment. In case of in vitro resistance against one component, except cis-platin, CAP therapy could cause even complete remission. With in vitro cis-platin resistance the maximum response with CAP treatment was partial remission.

UR - http://www.scopus.com/inward/record.url?scp=0022386770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022386770&partnerID=8YFLogxK

M3 - Article

C2 - 4060913

AN - SCOPUS:0022386770

VL - 107

SP - 1065

EP - 1071

JO - Aktuelle Dermatologie

JF - Aktuelle Dermatologie

SN - 0340-2541

IS - 17

ER -